The company will outline its progress and strategy during this month’s Proactive CEO Sessions. Chief executive officer Steven Lydeamore will present to investors at the Melbourne CEO Session on Tuesday, February 19.
Lydeamore has 26 years’ international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale.
Anatara’s product candidate GaRP is an evidence-based dietary supplement aimed at restoring and maintaining gut health. It is well advanced in proof of concept studies.
With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Animal health to human health
In October 2018, Anatara had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc.
The animal health product Detach has the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.
Following the successful licencing of its first product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.
Register for the CEO Sessions today to find out more.